Dabral Neha, Sriranganathan Nammalwar, Vemulapalli Ramesh
Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America.
Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America; Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.
PLoS One. 2014 Sep 16;9(9):e107180. doi: 10.1371/journal.pone.0107180. eCollection 2014.
Brucella spp. are Gram-negative, facultative intracellular coccobacilli that cause one of the most frequently encountered zoonosis worldwide. Humans naturally acquire infection through consumption of contaminated dairy and meat products and through direct exposure to aborted animal tissues and fluids. No vaccine against brucellosis is available for use in humans. In this study, we tested the ability of orally inoculated gamma-irradiated B. neotomae and B. abortus RB51 in a prime-boost immunization approach to induce antigen-specific humoral and cell mediated immunity and protection against challenge with virulent B. abortus 2308. Heterologous prime-boost vaccination with B. abortus RB51 and B. neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the production of serum and mucosal antibodies specific to the smooth LPS. The elicited serum antibodies included the isotypes of IgM, IgG1, IgG2a, IgG2b and IgG3. All oral vaccination regimens induced antigen-specific CD4(+) and CD8(+) T cells capable of secreting IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae showed the highest level of resistance against virulent B. abortus 2308 colonization in spleen and liver. Experiments with different doses of B. neotomae showed that all tested doses of 10(9), 10(10) and 10(11) CFU-equivalent conferred significant protection against the intra-peritoneal challenge. However, a dose of 10(11) CFU-equivalent of B. neotomae was required for affording protection against intranasal challenge as shown by the reduced bacterial colonization in spleens and lungs. Taken together, these results demonstrate the feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to induce protection against respiratory and systemic infections with virulent Brucella.
布鲁氏菌属是革兰氏阴性、兼性胞内球杆菌,可引发全球最常见的人畜共患病之一。人类通常通过食用受污染的乳制品和肉类产品以及直接接触流产动物的组织和体液而感染。目前尚无用于人类的布鲁氏菌病疫苗。在本研究中,我们采用初免-加强免疫方法,测试了经口服接种γ射线辐照的新墨西哥布鲁氏菌和流产布鲁氏菌RB51诱导抗原特异性体液免疫和细胞介导免疫以及抵御强毒流产布鲁氏菌2308攻击的能力。用流产布鲁氏菌RB51和新墨西哥布鲁氏菌进行异源初免-加强疫苗接种,以及用新墨西哥布鲁氏菌对小鼠进行同源初免-加强疫苗接种,均导致产生针对光滑脂多糖的血清抗体和黏膜抗体。诱导产生的血清抗体包括IgM、IgG1、IgG2a、IgG2b和IgG3等亚型。所有口服疫苗接种方案均诱导产生了能够分泌干扰素-γ和肿瘤坏死因子-α的抗原特异性CD4(+)和CD8(+) T细胞。经腹腔攻击后,用新墨西哥布鲁氏菌接种的小鼠对强毒流产布鲁氏菌2308在脾脏和肝脏中的定植表现出最高水平的抵抗力。用不同剂量新墨西哥布鲁氏菌进行的实验表明,所有测试剂量(相当于10(9)、10(10)和10(11) CFU)均能对腹腔攻击提供显著保护。然而,如脾脏和肺部细菌定植减少所示,需要相当于10(11) CFU的新墨西哥布鲁氏菌剂量才能提供针对鼻内攻击的保护。综上所述,这些结果证明了使用γ射线辐照的新墨西哥布鲁氏菌作为有效且安全的口服疫苗来诱导抵御强毒布鲁氏菌引起的呼吸道和全身感染的保护作用的可行性。